Research summary
Tesamorelin has been evaluated in published clinical trials, and it is approved as a medicine in some regions under a licensed product for a specific indication. Our research-grade material is a separate product and is not a medicine. This summary describes what the literature has investigated. It is not a claim about the effects of our product, which is supplied for laboratory research only.
Mechanism of action
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoyl group at the N-terminus that increases stability. It binds the GHRH receptor on pituitary somatotroph cells and stimulates growth hormone release.
Chemical properties
Structure: 44-residue GHRH analogue with an N-terminal trans-3-hexenoyl modification. Molecular weight: approx. 5.1 kDa. Form: lyophilised powder. Exact sequence, purity and identity: see the batch Certificate of Analysis (HPLC and mass spectrometry).
Storage and handling
Supplied as a lyophilised (freeze-dried) powder. Store sealed, cold, dry and protected from light, as stated on the Certificate of Analysis and product label. Allow the vial to reach room temperature before opening to limit condensation. Avoid repeated temperature cycling and humidity exposure. For laboratory research use only.
Literature references
Selected PubMed records on tesamorelin, scientific background only, not claims about our product. PMID 22298602: tesamorelin, a growth hormone-releasing factor analogue, in HIV-associated lipodystrophy (review). PMID 21283099 and PMID 31644039: tesamorelin drug monographs. Open any record at https://pubmed.ncbi.nlm.nih.gov/PMID/ . More: https://pubmed.ncbi.nlm.nih.gov/?term=tesamorelin
For laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice.
